Octave Bioscience nabs $32m Series B

Octave Bioscience, a developer of a care management platform for multiple sclerosis and other neurodegenerative diseases, has closed $32 million in Series B financing.

18 December 2020•4 mins read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles